- Home
- BAOS vs XRTX Comparison
BAOS vs XRTX Comparison
Compare BAOS & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAOS | XRTX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.3M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BAOS | XRTX |
|---|---|---|
| Price | $1.17 | $2.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 45.7K | 9.8K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.71 | $0.35 |
| 52 Week High | $5.40 | $3.60 |
Technical Indicators
Market Signals| Indicator | BAOS | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 22.10 | 44.71 |
| Support Level | N/A | $2.01 |
| Resistance Level | $2.98 | $2.28 |
| Average True Range (ATR) | 0.28 | 0.10 |
| MACD | -0.13 | 0.00 |
| Stochastic Oscillator | 4.09 | 27.91 |
Price Performance
Historical ComparisonAbout BAOS Baosheng Media Group Holdings
Baosheng Media Group Holdings Ltd is a China-based online marketing solution provider. The company provides internet marketing, short-video and V-log marketing, content production and operation, e-commerce marketing, data platform services, and AI technology-related services. It also offers customized marketing solutions and channel marketing services through partnerships with internet platforms such as Tencent, Alibaba, ByteDance, and Kuaishou.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.